在患有卵巢癌的患者中,年龄是Olaparib剂量修改和中止的危险因素
Hiroaki Inui1, Masayasu Sato1, Hiroyuki Yoshida1
1Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
Cancer diagnosis & prognosis
|July 4, 2024
概括
接受olaparib维持治疗的老年卵巢癌患者因不良事件 (AE) 而面临更高的剂量修改和治疗中止风险. 年龄是关键的风险因素,需要对老年患者进行谨慎的AE管理.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 一种PARP抑制剂Olaparib是卵巢癌的标准维持疗法.
- 剂量修改 (减少,中断) 是常见的管理olaparib的不良事件 (AEs).
- 识别处于剂量修改高风险的患者可以指导主动的AE管理.
研究的目的:
- 为了评估卵巢癌患者olaparib剂量修改的风险因素.
- 评估已识别的风险因素对预测治疗结果的临床有用性.
主要方法:
- 在60名接受olaparib治疗的卵巢癌患者进行了回顾性队列研究.
- 多变量逻辑回归分析,以确定患者特征和剂量修改之间的关联.
- 接收机运行特征 (ROC) 曲线分析,以确定风险分层的最佳年龄截止值.
主要成果:
- 41.7%的患者需要对olaparib剂量进行修改.
- 年龄较大 (p=0.018) 和倾向于体重不足 (p=0.078) 与剂量修改有关.
- 年龄的增加是剂量修改的重要独立风险因素 (OR=1.056,p=0.034).
- 剂量修改风险的最佳年龄截止值是65.0岁.
- 年龄≥65.0岁的患者因AEs (p=0.0437) 中断olaparib的可能性显著增加 (p=0.0437).
结论:
- 年龄的增加是卵巢癌中olaparib剂量修改的重要风险因素.
- 需要剂量修改的老年患者面临由于AEs的更高的治疗中止可能性.
- 严格的AE管理对于接受olaparib维持治疗的老年患者至关重要.
更多相关视频
13:04In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose
Published on: October 14, 2015
13.1K
09:40Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
2.6K
相关概念视频
02:07Oogenesis
63.6K
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
63.6K
01:21Cancer Survival Analysis
340
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
340
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
01:21Nondisjunction
3.8K
Nondisjunction is the failure of homologous chromosomes or sister chromatids to separate correctly and move to the opposite poles of the cells. This produces daughter cells with abnormal chromosome numbers. Nondisjunction is common during anaphase I or anaphase II of meiosis. Mutations in synaptonemal complex proteins that attach homologous chromosomes increase the chances of nondisjunction in anaphase I of meiosis I. In contrast, mutations in topoisomerases and condensins that hold...
3.8K